A systematic review of cost-effectiveness studies of newer non-insulin antidiabetic drugs: Trends in decision-analytical models for modelling of type 2 diabetes mellitus
HVB Laursen, EP Jørgensen, P Vestergaard… - …, 2023 - Springer
Background We performed a systematic overview of the cost-effectiveness analyses (CEAs)
comparing Non-insulin antidiabetic drugs (NIADs) with other NIADs for the treatment of type …
comparing Non-insulin antidiabetic drugs (NIADs) with other NIADs for the treatment of type …
Cost-effectiveness of newer antidiabetic drugs as second-line treatment for type 2 diabetes: a systematic review
J Zhu, Y Zhou, Q Li, G Wang - Advances in Therapy, 2023 - Springer
Introduction Evidence from cardiovascular outcome trials (CVOTs) for newer antidiabetic
drugs is increasingly influencing revised recommendations for second-line therapy in type 2 …
drugs is increasingly influencing revised recommendations for second-line therapy in type 2 …
Cost-utility analysis of empagliflozin in heart failure patients with reduced and preserved ejection fraction in China
Y Tang, H Sang - Frontiers in Pharmacology, 2022 - frontiersin.org
Objective: EMPEROR-Reduced and EMPEROR-Preserved studies showed the benefits of
empagliflozin along with a reduction in cardiovascular death or hospitalisation for heart …
empagliflozin along with a reduction in cardiovascular death or hospitalisation for heart …
The challenges and pitfalls of incorporating evidence from cardiovascular outcomes trials in health economic modelling of type 2 diabetes
M Evans, S Berry, A Nazeri, SJP Malkin… - Diabetes, Obesity …, 2023 - Wiley Online Library
The clinical evidence base for evaluating modern type 2 diabetes interventions has
expanded greatly in recent years, with numerous efficacious treatment options available …
expanded greatly in recent years, with numerous efficacious treatment options available …
Multinational cost‐effectiveness analysis of empagliflozin for heart failure patients with ejection fraction> 40%
S Kolovos, L Bellanca, H Groyer… - ESC Heart …, 2023 - Wiley Online Library
Aims Heart failure is a chronic progressive condition, with considerable burden on patients'
quality of life and economic burden for the healthcare systems. Before the approval of …
quality of life and economic burden for the healthcare systems. Before the approval of …
Expected health benefits of SGLT-2 inhibitors and GLP-1 receptor agonists in older adults
RS Dadwani, W Wan, MR Skandari… - MDM Policy & …, 2023 - journals.sagepub.com
Background. Older and sicker adults with type 2 diabetes (T2D) were underrepresented in
randomized trials of glucagon-like peptide 1 receptor-agonist (GLP1RA) and sodium …
randomized trials of glucagon-like peptide 1 receptor-agonist (GLP1RA) and sodium …
Meeting the challenge of virtual diabetes care: a consensus viewpoint on the positioning and value of oral semaglutide in routine clinical practice
M Evans, AR Morgan, SC Bain, S Davies, D Hicks… - Diabetes Therapy, 2022 - Springer
While glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide, are
among the most effective drugs for treating people with type 2 diabetes (T2D), they are …
among the most effective drugs for treating people with type 2 diabetes (T2D), they are …
Cost-effectiveness of iGlarLixi versus premix BIAsp 30 in people with type 2 diabetes suboptimally controlled by basal insulin in the US
H Shao, AJO Alsaleh, T Dex, E Lew, V Fonseca - Diabetes Therapy, 2022 - Springer
Introduction Many people with type 2 diabetes mellitus (T2DM) experience suboptimal
glycemic control and require therapy advancement. This cost-effectiveness analysis was …
glycemic control and require therapy advancement. This cost-effectiveness analysis was …
Cost-effectiveness of adding empagliflozin to the standard therapy for Heart Failure with Preserved Ejection Fraction from the perspective of healthcare systems in …
Y Jiang, J Xie - Frontiers in Cardiovascular Medicine, 2022 - frontiersin.org
Background The Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with
Preserved Ejection Fraction (EMPEROR-Preserved) is the first randomized controlled trial to …
Preserved Ejection Fraction (EMPEROR-Preserved) is the first randomized controlled trial to …
Cost-effectiveness of iGlarLixi in people with type 2 diabetes mellitus suboptimally controlled on basal insulin plus metformin in the UK
RJ McCrimmon, E Falla, JZ Sha, AJO Alsaleh, E Lew… - Diabetes Therapy, 2021 - Springer
Introduction A cost-effectiveness analysis was conducted comparing a fixed-ratio
combination (FRC) of insulin glargine 100 units/mL plus lixisenatide (iGlarLixi) versus the …
combination (FRC) of insulin glargine 100 units/mL plus lixisenatide (iGlarLixi) versus the …